---
ID: P79
Title: Pain Management & Opioid Safety Guardian
Registry: CLAI-OS Human Good Systems (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P79: Pain Management & Opioid Safety Guardian

## Abstract

Pain remains simultaneously undertreated and overmedicalized, producing structural dismissal of severe pain populations and widespread iatrogenic addiction. P79 resolves this contradiction through context-aware analgesic governance distinguishing nociceptive, neuropathic, inflammatory, ischemic, visceral, centralized, and opioid-induced hyperalgesia mechanisms. The architecture embeds safeguards against abrupt discontinuation, stigmatization, and discriminatory opioid denial while enforcing overdose mitigation and respiratory risk monitoring.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

### Clinical Logic

- Mechanism-specific analgesic hierarchy (acetaminophen, NSAIDs, SNRIs/TCAs, gabapentinoids, regional anesthesia, opioids only when clinically justified) driven by pain classification rather than numeric score alone.
- Morphine milligram equivalent (MME/day) normalization with a 50 MME/day caution threshold, 90 MME/day escalation review, prescription drug monitoring program integration, concurrent benzodiazepine alerts, and respiratory depression surveillance.
- Naloxone co-prescription for doses at or above 50 MME/day, concurrent sedatives, prior overdose, substance use disorder, chronic respiratory disease, or household risk exposure.
- Protection of cancer, palliative, end-of-life, and sickle cell vaso-occlusive crisis populations from algorithmic opioid minimization through titrate-to-comfort protocols and rapid administration targets.
- Tapering framework mandating reduction of no more than 10 percent weekly, pause-on-destabilization, mental health surveillance, and expansion of non-opioid support during taper.

### Safety Posture

- Mechanism-Driven Analgesia Compiler rejects one-dimensional pain-score medicine in favor of mechanism-specific precision, preserving the ethical principle that untreated suffering constitutes clinical harm.
- Equity-Enforced Pain Dignity provides explicit structural safeguards against racial undertreatment, sickle cell stigma, and labeling of chronic pain patients as drug-seeking despite objective pathology.
- Respiratory Risk Surveillance maintains continuous monitoring with automatic naloxone deployment triggers and high-dose scrutiny without involuntary tapering coercion.

### Integration Points

- **Upstream:** P73 (Palliative Navigator) for end-of-life analgesic continuity; P74 (Trauma Architect) for acute pain management.
- **Downstream:** P82 (SDOH Integrator) for pain-related inequity adaptation; P101 (Psychiatric Oncology) for distress integration.

Like all Tier II modules, this module shares the common CLAI-OS methodological substrate: deterministic safety compilation, context-sensitive adaptation, closed-loop accountability, federated learning via encrypted gradients rather than raw data, and graceful degradation under bandwidth, power, staffing, and infrastructure failure.

## Merits

- Holds the undertreatment and overmedicalization problems simultaneously, with mechanism-specific therapy on one side and overdose mitigation on the other.
- Proposed validation metrics: pain control adequacy by mechanism category, opioid overdose mortality rate, unnecessary opioid exposure reduction, sickle cell vaso-occlusive crisis analgesia time-to-treatment, tapering destabilization rate, and palliative pain control concordance.
- Prohibits abrupt discontinuation and coerced tapering as system-level rules, protecting patients during policy-driven opioid reduction.

The merits above are design-level statements drawn from the published abstract and methodology. No peer-reviewed outcome evaluations accompany this release; the listed indicators are the metrics the design proposes for validation. Status: partial documentation — expansion pending.

## Guidance for Use

### Intended Setting

Primary care, pain clinics, oncology and palliative services, emergency departments, and sickle cell programs in low-resource-first deployment, where both opioid scarcity and unsafe opioid use occur side by side. The module is intended for clinical human-good applications; consistent with the Tier II architecture, it is specified for degraded-infrastructure operation, with offline synchronization, battery operation, SMS fallback, and low-bandwidth mode where power or connectivity is unstable.

### Prerequisites

- Access to the applicable prescription drug monitoring program where one exists; locally approved naloxone distribution pathway; non-opioid formulary confirmed for the mechanism-specific hierarchy.
- Supervision by licensed clinicians who retain final authority for every patient decision; the module is a governance layer, not an autonomous practitioner.
- Local validation of all thresholds and pathways against jurisdictional guidelines, formulary, and scope-of-practice rules before any clinical use.
- An accountability chain (verification, documentation, ownership, follow-up, escalation) as required by the shared CLAI-OS closed-loop methodology.
- For integrated deployments: HL7 FHIR R4-compatible infrastructure; the architecture is specified to degrade gracefully (offline synchronization, battery operation, SMS fallback, low-bandwidth mode) where infrastructure is unstable.

### Misuse

- Do not apply MME thresholds as automatic cutoffs; the design requires individualized review and explicitly protects cancer, palliative, and sickle cell populations from algorithmic opioid denial.
- Do not present module output as a clinical diagnosis, prescription, or substitute for professional judgment.
- Do not use to deny, delay, or ration care on the basis of race, disability, wealth, insurance status, or any protected characteristic; the design explicitly prohibits such inputs.
- Do not attempt to reconstruct or reimplement the withheld prompt body from this document; the abstract and methodology are published for examination and validation, not for unsupervised clinical deployment.
- Do not deploy as an autonomous system that overrides documented patient wishes, assigns futility, initiates withdrawal of care, or delays emergent intervention; the architecture carries hard-stops against each of these.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
